News MedicalResearchers Followed Glucose Monitor Users for Three Years and Found a Possible Kidney Benefit

ℹ️ Observational Association Only Evidence

In an observational target-trial emulation involving 25,371 adults with type 2 diabetes, sustained real-time continuous glucose monitoring was associated with lower HbA1c through three years and lower urinary albumin-creatinine ratio at year 3. eGFR findings did not demonstrate kidney-function preservation. Substantial discontinuation, crossover, and attrition limit causal interpretation of the longer-term kidney signal.

Clinical Considerations

• At 1 year, mean HbA1c was 7.83% with rtCGM versus 8.93% without initiation, a 1.10-percentage-point difference.
• The glycemic association persisted at 3 years, when mean HbA1c was 7.83% versus 8.58%, a 0.75-point difference.
• UACR did not significantly differ during the first 2 years but was 153 versus 278 mg/g at year 3 among available participants.
• eGFR did not show preserved kidney filtration associated with sustained rtCGM use over three years.
• Longer-term kidney findings require particular restraint because 44.3% of rtCGM initiators discontinued monitoring, and only 331 rtCGM initiators remained in the 3-year UACR analysis.
• The observational design and residual confounding prevent attributing the UACR difference directly to rtCGM or improved glycemic control.

Practice Applications

• Recognize sustained rtCGM use as associated with durable glycemic improvement in this high-risk T2D cohort.
• Interpret the 3-year albuminuria finding as an observational signal rather than evidence that CGM slows kidney disease.
• Avoid using the UACR finding as evidence of kidney-function preservation because the study found no corresponding eGFR benefit.
• Monitor established renal measures independently of CGM-derived glycemic information in patients at elevated kidney risk.
• Discuss CGM according to established diabetes-management indications rather than adding kidney protection as an established benefit.